PMID- 19379142
OWN - NLM
STAT- MEDLINE
DCOM- 20090804
LR  - 20211020
IS  - 1582-4934 (Electronic)
IS  - 1582-1838 (Print)
IS  - 1582-1838 (Linking)
VI  - 13
IP  - 3
DP  - 2009 Mar
TI  - Drug releasing systems in cardiovascular tissue engineering.
PG  - 422-39
LID - 10.1111/j.1582-4934.2008.00532.x [doi]
AB  - Heart disease and atherosclerosis are the leading causes of morbidity and 
      mortality worldwide. The lack of suitable autologous grafts has produced a need 
      for artificial grafts; however, current artificial grafts carry significant 
      limitations, including thrombosis, infection, limited durability and the 
      inability to grow. Tissue engineering of blood vessels, cardiovascular structures 
      and whole organs is a promising approach for creating replacement tissues to 
      repair congenital defects and/or diseased tissues. In an attempt to surmount the 
      shortcomings of artificial grafts, tissue-engineered cardiovascular graft 
      (TECVG), constructs obtained using cultured autologous vascular cells seeded onto 
      a synthetic biodegradable polymer scaffold, have been developed. Autologous 
      TECVGs have the potential advantages of growth, durability, resistance to 
      infection, and freedom from problems of rejection, thrombogenicity and donor 
      scarcity. Moreover polymers engrafted with growth factors, cytokines, drugs have 
      been developed allowing drug-releasing systems capable of focused and localized 
      delivery of molecules depending on the environmental requirements and the milieu 
      in which the scaffold is placed. A broad range of applications for 
      compound-releasing, tissue-engineered grafts have been suggested ranging from 
      drug delivery to gene therapy. This review will describe advances in the 
      development of drug-delivery systems for cardiovascular applications focusing on 
      the manufacturing techniques and on the compounds delivered by these systems to 
      date.
FAU - Spadaccio, Cristiano
AU  - Spadaccio C
AD  - Cardiac and Molecular Biology Laboratory, Heart, Lung & Esophageal Surgery 
      Institute University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
FAU - Chello, Massimo
AU  - Chello M
FAU - Trombetta, Marcella
AU  - Trombetta M
FAU - Rainer, Alberto
AU  - Rainer A
FAU - Toyoda, Yoshiya
AU  - Toyoda Y
FAU - Genovese, Jorge A
AU  - Genovese JA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - J Cell Mol Med
JT  - Journal of cellular and molecular medicine
JID - 101083777
RN  - 0 (Biocompatible Materials)
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Animals
MH  - Biocompatible Materials
MH  - *Cardiovascular System
MH  - Drug Delivery Systems/*methods
MH  - Humans
MH  - Pharmaceutical Preparations
MH  - Tissue Engineering/*methods
PMC - PMC3822506
EDAT- 2009/04/22 09:00
MHDA- 2009/08/06 09:00
PMCR- 2009/03/01
CRDT- 2009/04/22 09:00
PHST- 2009/04/22 09:00 [entrez]
PHST- 2009/04/22 09:00 [pubmed]
PHST- 2009/08/06 09:00 [medline]
PHST- 2009/03/01 00:00 [pmc-release]
AID - JCMM532 [pii]
AID - 10.1111/j.1582-4934.2008.00532.x [doi]
PST - ppublish
SO  - J Cell Mol Med. 2009 Mar;13(3):422-39. doi: 10.1111/j.1582-4934.2008.00532.x.